← All peptides

Peptide data sheet

VK2735

VK2735

GLP-1 · Viking VK2735

Verdict

promising

The promising label reflects the encouraging early-phase human data reported for VK2735 in both its injectable and oral forms; it is tempered by the fact that the compound is still investigational, not FDA-approved, has no phase-3 outcome data yet, and the research-grade material sold for lab use is not the trial drug.

By MrPepTalks Editorial

Reviewed for scientific accuracy · research information, not medical advice

Last updated Reviewed

Quick answer

VK2735 is an investigational peptide from Viking Therapeutics that acts on two metabolic receptors, GLP-1 and GIP. It is most commonly researched for weight management, and it is notable for being developed in both an injectable and an oral tablet form. It is still investigational and not FDA-approved; research-grade VK2735 sold for laboratory use is not the trial drug.

At a glance
Class
Dual agonist (GLP-1 / GIP receptor)
Half-life
reported as long enough to support once-weekly injectable research dosing; the oral form is dosed on a separate schedule
FDA status
Not FDA-approved. VK2735 is an investigational compound still in clinical trials; research-grade material sold for lab use is intended for laboratory research only.
WADA banned?
No

Which form actually works?

Injectable (subcutaneous)

Promising

The injectable form is where VK2735's most-discussed human data sits — the phase-2 VENTURE obesity study reported its weight results here. People report interest in this form because it matches how the compound was actually studied.

Oral (tablet)

Unproven

An oral tablet form is a genuine part of Viking's program and a big reason for the attention, since most metabolic peptides are injection-only. But the oral data is earlier-stage than the injectable data, so the evidence sits lower here.

Third-Party Testing & Certificate of Analysis (COA)

A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.

HPLC — purity
High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
Mass spectrometry (MS) — identity
Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.

It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.

New to reading one? This guide walks through a COA line by line: how to read a peptide COA.

Sources

  1. Viking Therapeutics VK2735 (dual GIP/GLP-1 receptor agonist) clinical program record.
  2. Phase 1 study of subcutaneous VK2735 in adults with obesity (dose-ranging).
  3. Phase 1 study of oral VK2735 tablet formulation in adults with obesity.

Related peptides

All GLP-1

Frequently asked questions

Send it to me →

No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.